
July 23 (Reuters) - ANI Pharmaceuticals Inc ANIP.O:
ANI PHARMACEUTICALS ANNOUNCES RESULTS FROM NEW DAY CLINICAL TRIAL OF ILUVIEN® FOR USE IN PATIENTS WITH DIABETIC MACULAR EDEMA (DME)
ANI PHARMACEUTICALS INC - PRIMARY ENDPOINT WAS MEAN NUMBER OF SUPPLEMENTAL AFLIBERCEPT INJECTIONS
ANI PHARMACEUTICALS INC - ILUVIEN SHOWED NUMERICAL REDUCTION IN INJECTIONS BUT NOT SIGNIFICANT
ANI PHARMACEUTICALS INC - SECONDARY ENDPOINT MET WITH MEAN TIME OF 185.4 DAYS IN ILUVIEN ARM
ANI PHARMACEUTICALS INC - ILUVIEN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE IN TRIAL